The Oncology Institute, Inc.
NASDAQ:TOIMedical - Care Facilities
-$0.07 today
- Market cap
- $512.91M
- Beta
- 0.41
- P/E (TTM)
- -121.1
- EPS (TTM)
- -$0.04
Volume 1.21M
Average 1.74M
TOI Operating Cash Flow
Cash generated by the company's core business operations during the period.
The Oncology Institute, Inc.NASDAQ: TOI
Operating Cash Flow · Q1 FY2026 · quarter ended Mar 2026
Operating cash flow dips below year-ago levels
Q1 FY2026 operating cash flow of $2.22M (cash outflow) fell 55.6% year over year, behind the +39.4% change in trailing-twelve-month operating cash flow. Over 3 fiscal years it compounded at -26.4% a year.
Context
- Operating cash flow amounted to 4.9% of revenue in FY2025, down 1.9 pp from a year earlier.
- Operating cash flow grew in size in 0 of the last 3 fiscal years.
- FY2025 was the smallest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from -55.6% toward the trailing-twelve-month pace of +39.4%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Operating Cash Flow history
USD · from the cash flow
- Latest · FY2025
- (24.59M) USD
- Year-over-year change
- +7.4%
| Period | Period end | Operating Cash Flow | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (24.59M) | +7.4% |
| FY2024 | 2024-12-31 | (26.54M) | +26.9% |
| FY2023 | 2023-12-31 | (36.32M) | +41.2% |
| FY2022 | 2022-12-31 | (61.76M) | -89.0% |
| FY2021 | 2021-12-31 | (32.68M) | — |
Operating Cash Flow vs competitors
How TOI compares with its peers on the latest reported figures
- Peers report in different currencies, so operating cash flow is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +39.4% is the 2nd highest of 10, against a peer median of -3.1%.
- Operating cash flow amounts to 4.0% of revenue for TOI, versus a peer median of 6.2%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
AUNAAuna S.A. | LTM Mar 2026 | PEN 601.05M PEN | -3.1% | +14.3% | 13.3% |
| LTM Mar 2026 | $273.32M USD | +13.3% | +36.2% | 295.2% | |
| LTM Mar 2026 | $50.05M USD | +19.2% | -6.8% | 0.9% | |
CBLLCeriBell, Inc. | LTM Mar 2026 | $48.85M USD | +32.4% | +8.4% | 51.4% |
| LTM Mar 2026 | $47.34M USD | -60.5% | -28.9% | 4.7% | |
| LTM Mar 2026 | $36.59M USD | +59.0% | -20.7% | 12.1% | |
| LTM Mar 2026 | $21.81M USD | +39.4% | -26.4% | 4.0% | |
| LTM Mar 2026 | $15.35M USD | -349.7% | — | 3.7% | |
| LTM Mar 2026 | $12.93M USD | -49.8% | -19.5% | 6.2% | |
| LTM Mar 2026 | $3.98M USD | -84.0% | -39.4% | 1.6% | |
| Peer median (excluding TOI) | — | -3.1% | -13.2% | 6.2% | |
Competitors are the stored peer set for TOI. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (10.93M) | 152K | (83.07M) | (53.01M) | (60.61M) |
| Depreciation & Amortization | 3.34M | 4.41M | 5.87M | 6.29M | 6.94M |
| Deferred Income Tax | (1.24M) | (263K) | (76K) | 0 | (32K) |
| Stock-Based Compensation | 24.54M | 27.68M | 17.81M | 11.15M | 4.55M |
| Change in Working Capital | (14.49M) | (20.54M) | 2.36M | 18.06M | 1.33M |
| Accounts Receivables | (2.99M) | (19.67M) | (4.5M) | (5.77M) | (12.58M) |
| Inventory | (1.84M) | (1.73M) | (4.39M) | 3.64M | (6.84M) |
| Accounts Payables | 2.92M | (6.19M) | 5.06M | 9.22M | 19.64M |
| Other Working Capital | (12.58M) | 7.04M | 6.19M | 10.98M | 1.11M |
| Other Non-Cash Items | (33.9M) | (73.2M) | 20.79M | 2.12M | 23.23M |
| Operating Cash Flow | (32.68M) | (61.76M) | (36.32M) | (26.54M) | (24.59M) |
| Capital Expenditures | (3.05M) | (5.53M) | (4.57M) | (3.79M) | (3.2M) |
| Acquisitions (Net) | (9.11M) | (8.58M) | (4.46M) | 0 | 0 |
| Purchases of Investments | 0 | (117.51M) | (9.6M) | 0 | 0 |
| Sales of Investments | 0 | 0 | 81.26M | 50M | 126K |
| Other Investing Activities | (200K) | 0 | 0 | 0 | 0 |
| Investing Cash Flow | (12.15M) | (131.61M) | 62.64M | 46.21M | (3.07M) |
| Debt Repayment | (7.25M) | 109.94M | (101K) | (39K) | (20.04M) |
| Common Stock Issued | 0 | 0 | 0 | 75K | 32.63M |
| Common Stock Repurchased | 0 | (9M) | (1.02M) | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 141.26M | (8.74M) | (5.73M) | (3.53M) | (1.04M) |
| Financing Cash Flow | 154.01M | 92.21M | (6.85M) | (3.49M) | 11.56M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 109.18M | (101.16M) | 19.48M | 16.18M | (16.1M) |
| Free Cash Flow | (35.73M) | (67.29M) | (40.88M) | (30.33M) | (27.79M) |
The Oncology Institute, Inc.
NASDAQ:TOI
Intrinsic Alpha fair value
Locked
Current Price
$5.13
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.